Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the transaction, the insider owned 3,885,115 shares in the company, valued at $27,700,869.95. This represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00.
• On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.11, for a total value of $273,735.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.17, for a total value of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Trading Down 9.7%

Shares of Entrada Therapeutics stock opened at $6.42 on Friday. The company’s 50-day moving average price is $7.02 and its two-hundred day moving average price is $9.06. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45. The stock has a market cap of $249.99 million, a PE ratio of -1.62 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. On average, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Neutral Sentiment: Entrada announced two recipients of its 2026 DREAMS Grant Program, awarding $50,000 each to projects addressing healthcare disparities and improving outreach to underserved members of the global Duchenne muscular dystrophy community. The initiative supports the company’s patient-focused reputation, although the grants are not expected to have a significant direct financial impact. Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
• Neutral Sentiment: A report showing short interest of zero shares and a zero-day days-to-cover ratio appears internally inconsistent, including a reported “NaN” percentage change. As a result, it provides no meaningful indication of short-selling pressure or potential for a short squeeze.
• Negative Sentiment: Major shareholder Bioventures 2018 L.P. MPM disclosed additional sales of TRDA shares, including 28,837 shares on September 9 for approximately $206,000 and 192,500 shares on September 8 for about $1.43 million. The shareholder also sold shares in earlier September transactions, bringing the reported series to more than 433,000 shares. Although the fund still owns a substantial stake, repeated insider disposals can weigh on investor confidence and increase perceived supply. Entrada Therapeutics Major Shareholder Share Sale

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after acquiring an additional 42,479 shares during the last quarter. Rhumbline Advisers boosted its position in Entrada Therapeutics by 8.3% during the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock valued at $263,000 after purchasing an additional 2,982 shares during the last quarter. American Century Companies Inc. grew its stake in Entrada Therapeutics by 10.8% in the second quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock valued at $505,000 after purchasing an additional 7,301 shares in the last quarter. Prudential Financial Inc. grew its stake in Entrada Therapeutics by 23.4% in the second quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock valued at $190,000 after purchasing an additional 5,370 shares in the last quarter. Finally, Invesco Ltd. increased its position in Entrada Therapeutics by 34.2% in the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock worth $150,000 after purchasing an additional 5,702 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on TRDA shares. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Guggenheim dropped their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.